Controlled release dosage forms
DCFirst Claim
Patent Images
1. A pharmaceutical oral dosage form comprising an oral dosage form coated with a stable controlled release monolithic coating, wherein the stable controlled release monolithic coating is applied onto the oral dosage form by a process comprisingcoating the oral dosage form with a coating composition to form a coated oral dosage form, andcuring the coated oral dosage form at a temperature of at least 55°
- C. to form the stable controlled release monolithic coating,wherein the coating composition consists essentially ofa neutral ester copolymer in an amount of from about 1% to about 35% by weight of the coating composition based on ethyl acrylate and methyl acrylate selected from the group consisting of a 30% aqueous dispersion of a neutral ester copolymer based on ethyl acrylate and methyl methacrylate, a 40% aqueous dispersion of a neutral ester copolymer based on ethyl acryl ate and methyl methacrylate, and combinations thereof;
a polyethylene glycol selected from the group consisting of polyethylene glycol 6000, polyethylene glycol 8000, polyethylene glycol 10000, polyethylene glycol 20000, and combinations thereof in an amount of from about 0.1% to about 3% by weight of the coating composition; and
one or more of a hydrophilic agent, and a pharmaceutically acceptable excipient.
24 Assignments
Litigations
0 Petitions
Accused Products
Abstract
The invention provides stable controlled release monolithic coating compositions for use in coating pharmaceutical oral dosage forms comprising a polyglycol having a melting point greater than 55° C. and an aqueous dispersion of a neutral ester copolymer lacking functional groups.
-
Citations
6 Claims
-
1. A pharmaceutical oral dosage form comprising an oral dosage form coated with a stable controlled release monolithic coating, wherein the stable controlled release monolithic coating is applied onto the oral dosage form by a process comprising
coating the oral dosage form with a coating composition to form a coated oral dosage form, and curing the coated oral dosage form at a temperature of at least 55° - C. to form the stable controlled release monolithic coating,
wherein the coating composition consists essentially of a neutral ester copolymer in an amount of from about 1% to about 35% by weight of the coating composition based on ethyl acrylate and methyl acrylate selected from the group consisting of a 30% aqueous dispersion of a neutral ester copolymer based on ethyl acrylate and methyl methacrylate, a 40% aqueous dispersion of a neutral ester copolymer based on ethyl acryl ate and methyl methacrylate, and combinations thereof; a polyethylene glycol selected from the group consisting of polyethylene glycol 6000, polyethylene glycol 8000, polyethylene glycol 10000, polyethylene glycol 20000, and combinations thereof in an amount of from about 0.1% to about 3% by weight of the coating composition; and one or more of a hydrophilic agent, and a pharmaceutically acceptable excipient. - View Dependent Claims (2, 3)
- C. to form the stable controlled release monolithic coating,
-
4. A method of manufacturing a pharmaceutical oral dosage form coated with a stable controlled release monolithic coating, the method comprising
coating the oral dosage form with a coating composition to form a coated oral dosage form, and curing the coated oral dosage form at a temperature of at least 55° - C. to form the stable controlled release monolithic coating,
wherein the coating composition consists essentially of a neutral ester copolymer based on ethyl acrylate and methyl acrylate selected from the group consisting of a 30% aqueous dispersion of a neutral ester copolymer based on ethyl acrylate and methyl methacrylate, a 40% aqueous dispersion of a neutral ester copolymer based on ethyl acrylate and methyl methacrylate, and combinations thereof in an amount of from about 1% to about 35% by weight of the coating composition; a polyethylene glycol selected from the group consisting of polyethylene glycol 6000, polyethylene glycol 8000, polyethylene glycol 10000, polyethylene glycol 20000, and combinations thereof in an amount of from about 0.1% to about 3% by weight of the coating composition; and one or more of a hydrophilic agent, and a pharmaceutically acceptable excipient. - View Dependent Claims (5, 6)
- C. to form the stable controlled release monolithic coating,
Specification